In several human studies, adiponectin has been found to be associated with a number of cancer types: decreased in breast and endometrial cancer but increased in nonsmall cell lung cancer, prostate, gastric, liver, pancreatic, and hematological cancers, colon cancer, and renal cell carcinoma [131–134]. In vitro studies suggested that in certain cancers, such as colorectal, breast, and liver cancers, adiponectin promotes tumor growth, while in others it suppresses it [64]. Here, ADIPOQ is linked to endometrial cancer.